Lv5
905 积分 2021-02-26 加入
Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins
3天前
已完结
Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)
1个月前
已关闭
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease
1个月前
已完结
An update on treatment and outcomes for alcoholic hepatitis
1个月前
已完结
精性肝炎临床治疗进展
1个月前
已完结
The devolution of biosimilars regulations
2个月前
已完结
异基因造血干细胞移植急性移植物抗宿主病诊断与治疗中国专家共识
3个月前
已完结
长舒霖®和来得时®治疗2型糖尿病的有效性和安全性比较:多中心、随机、开放、平行、Ⅲ期临床研究
3个月前
已完结
两种甘精胰岛素治疗糖尿病的疗效及安全性比较：多中心、随机、开放、对照试验
3个月前
已完结
Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study
4个月前
已完结
皖公网安备34019202002308
